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In the last three decades or so digital technologies have penetrated into a vast array of human 
activities; smart phones, computers, internet, social media and the rest have not only reached into 
many domains of everyday life, but also they have spread globally and very rapidly at a speed that 
technologies from previous eras had not done. In this special themed issue of the AJPM a series of 
papers explore some of the implications of digital technologies for disease prevention and public 
health.  Presently the potential for such interventions appears to be extensive including surveillance 
of population information, continuous self-monitoring of bodily signs, symptoms and measures, 
through prompts to assist and support behaviour changes, to provision of advice and guidance about 
lifestyle and health risks.  There are a number of questions that deserve detailed scientific attention 
and the papers in this volume contribute to that consideration.   
First unintended consequences: the inventors, pioneers, innovators and advocates of earlier 
technical revolutions did not foresee with very much accuracy the direction that their new 
technologies would take.  The printing press, the steam engine, canals, the electric motor, the 
postage stamp, television and railways were not originally devised with anything like full knowledge 
of all the many diverse ways in which these technologies eventually developed and subsequently 
shaped society.  The technologies went in directions of their own.  So it seems likely, given that it is 
comparatively early days in respect of digital technologies applied to disease prevention, that some 
of the uses we imagine for digital technologies now, will appear to succeeding generations to be 
quaintly misguided.  The way the technologies do eventually get used on a regular and sustained 
basis we have yet to see.  That these technologies will have uses and effects for good and / or ill is 
clear; what we don’t know is what those benefits and dis-benefits are likely to be.  This collection of 
papers shows that the science of understanding the impacts and the mechanisms of action of these 
technologies is as yet, largely underdeveloped.   
Second, it is easy, but misguided, to talk about digital technologies as if they were one thing.  They 
are computer based and digital and they sit on electronic platforms and can be used on devices that 
share a common IT heritage.  But obviously that does not mean that they are the same or will work 
in the same way.  Just because things are IT based does not mean that the psychological or social 
response to the devices and any interventions that they carry will be similar.  The ways that people 
engage with the technologies, the mechanism of action, the human responses and the outcomes will 
be heterogeneous.  Of course there will be classes of devices and stimuli emanating from them that 
may share characteristics, but as yet it is not clear what those classes of devices or actions or 
outcomes are. Conceptually we are far from precise about the things called digital technologies.  
Third, as these papers show, it is not yet clear what the optimal scientific way is that we should study 
these objects and their effects.  As evidence based medicine has become established a series of tried 
and trusted methods have been refined to assess effectiveness, efficacy and the cost effectiveness 
of new drugs, devices or new interventions to prevent disease.  The Randomised Control Trial is the 
cornerstone of this approach and we have learned much over the last several decades about the 
strengths and the limitations of this method and associated approaches like systematic reviewing 
and evidence synthesis.  What emerges in this collection of papers is that these methods will need to 
be revisited with respect to digital technologies.  One of the core problems is the speed of evolution 
of the technologies compared to the conventional pace of scientific research, development and 
evaluation in medical science.  The pace of change of the technologies is much faster than 
conventional research designs can keep up with – and yet it is vital to continue to provide users and 
policy-makers with high quality evidence about the cost-effectiveness of digitally-delivered 
healthcare.  It is clear that new research designs will have to be developed, otherwise we are likely 
to be rather like astronomers gazing through an optical telescope in the hope of picking up signals 
from invisible distant galaxies.  The scientific method will need to reflect the nature of the 
phenomena we are studying rather than the principles of past scientific successes. This also applies 
to the way the cost effectiveness of the new technologies are assessed and evaluated.  A set of 
methods has been developed to permit the reliable and consistent comparison of the cost 
effectiveness of technologies and of conducting preventive activities.  The need to extend these 
methods in order to capture the particular issues arising in digital technologies will be an emerging 
area in health economics in ways that as yet remain to be explored. 
Fourth, there are implications for the traditional doctor patient relationship and public health 
experts and the populations they serve.  This relationship is conventionally grounded in notions of 
expertise and the closure of knowledge along with patient or public dependence on professional 
expertise.  The availability of masses of information to anyone with a device about anything that 
may be wrong with them or the many risks attaching to being alive, has certainly ended the strictly 
demarcated social closure of medical knowledge.  But of course information isn’t knowledge, and 
information doesn’t equate to expertise.  It is easy to glibly talk about expert patients and about the 
availability of information transforming the doctor patent relationship; but precisely how?  Does 
traditional clinical advice on for example the perils of smoking, alcohol misuse, or being overweight 
become redundant as the patient can themselves access the epidemiological sources describing 
risks? Or are the messages diluted because of the availability of junk information vying for attention 
amidst the peer reviewed science?  Undoubtedly the presence of mega information has the capacity 
to change things, but it is not at all clear yet how.   
Fifth, new ethical issues emerge as a consequence of the use of these technologies.  The degree to 
which the opportunities for surveillance offered by the digital traces left by our engagement with 
technologies and the continuous monitoring of bio signs and symptoms that can be collected from 
populations is unprecedented.  Current legislation on data protection and informed consent lags 
well behind the potential that these new technologies offer and the ethical principles raised remain 
relatively under discussed – the issue is not raised in this set of papers for example. Whether one 
sees this as the Foucauldian nightmare of the Benthamite panoptican about to come to pass or an 
amazing opportunity to observe population health is not just an interesting debate.   Quite possibly 
we are on the verge of something analogous to the invention of X-ray imaging but for populations.   
The new technologies will allow us to “see inside” the population in ways that have never before 
been possible.  The linkage of digital data with our knowledge of the metabolome might yet prove to 
be the most significant development in medicine of the last 50 years.  But how to regulate all this 
and what the challenge to our ethical principles might be, remain pressing questions.  
Finally, the methods we use as scientist are premised on a set of, usually implicit, epistemic 
assumptions.  These are the assumptions that determine what is and isn’t considered to be 
admissible knowledge for our models, theories and evidence.  As the papers in this volume 
demonstrate as new methods evolve, new epistemic assumptions will also need to evolve and 
professionally we need to be keenly aware of their implications for our science and our practice. One 
critical example of this is about in the relations between individual and population health.  As you 
read through the papers in this volume it will become clear that most of the working assumptions 
about the engagement, mechanisms of action and outcomes of digital technologies are located at 
the level of the individual.  The putative devices and interventions are aimed at discrete individuals 
often in highly personalised ways.  The assumption which follows is that population health effects 
will be the consequence of the aggregation of all the individual effects.   
While this will of course be true, we will need to be mindful of the fact that public health also uses 
another different epistemic assumption which is that populations are not just the statistical 
aggregation of millions of individuals; populations have a reality and analytic level of their own.  
Here phenomena that manifest themselves at population level such as the patterning of health 
inequalities or the actions of the wider determinants of health like poverty, disadvantage, and 
economic and political processes operate.  If our starting assumption is that the current epidemics of 
non-communicable disease only originate in the lifestyle behaviours of individuals, that the solution 
is more and better ways of changing these lifestyle behaviours and that digital technologies offer a 
more effective way of doing this than our erstwhile methods of health education and behaviour 
change, we might not make very much progress.   
The epidemics of non-communicable disease are the product of the actions of often global agents 
selling populations large quantities of energy dense fatty, salty, sugary products of non-optimal 
nutritional value and cheap and easily available alcohol. The epidemics are also the product of 
environments where it is difficult to walk or exercise, with the tobacco industry forever hovering in 
the background ready to seize the commercial initiative given half a chance.  Digital technologies 
have and will become intrinsic to these environments.  So it is not so much that we should not think 
about new ways in which digital technologies may help people individually take more exercise, 
monitor their blood sugar, or drink less alcohol.  Rather we must also reflect on the nature of digital 
technologies working at the distinct population level.  The papers in this collection show that this is 
conceptually quite difficult. We also have to be savvy about our enthusiasm for the new.  Anti-health 
forces would be delighted if we switched all our preventive attention to individually based digital 
behaviour change technologies because it lets them right off the hook.  Both the individual and 
social levels of analysis intrinsic to public health with their different epistemic assumptions must be 
uppermost in our collective research minds as we think about the digital landscape as it might look 
in ten, twenty or even thirty years’ time.  
We hope that this cross and interdisciplinary collection of papers from scholars around the world will 
help not just elucidate some of the issues but prompt debate and discussion about this exciting field 
and perhaps move some of the scientific questions forward. 
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